2008-07-24 12:35:03 -
www.epixpharma.com - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it is scheduled to make two presentations at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease in Chicago.
Sharon Shacham, Ph.D., senior
vice president of drug development at EPIX is scheduled to present "Stimulation of Serotonin Type 4 Receptors Leads to Increases in Alpha-Secreatase Activity and sAPPalpha: Potential for Disease Modification in Alzheimer's Disease" on Tuesday, July 29, 2008 at approximately 11:45 a.m. (CT). Dr. Shacham's presentation will take place during the Disease Mechanisms: Signal Transduction Oral Session of the conference.
J. Thomas Megerian, M.D., Ph.D., executive director for clinical development at EPIX, is scheduled to present "Results of a Phase 2a Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer's Disease" on Wednesday, July 30, 2008 at 12:00 p.m. (CT). Dr. Megerian's presentation will take place during the Hot Topics Oral Session of the conference.
In May 2008, EPIX announced the initiation of a Phase 2b proof-of-concept program for PRX-03140 that consists of two clinical trials - a six-month trial evaluating PRX-03140 in combination with donepezil and a three-month trial studying PRX-03140 as monotherapy. PRX-03140 is part of EPIX's strategic collaboration with GlaxoSmithKline, which is conducted through GSK's Center of Excellence for External Drug Discovery (CEEDD).
About the GSK CEEDD
GlaxoSmithKline is enhancing the way it discovers and develops drugs by creating a small dedicated team who will feed the GSK pipeline through the efforts of its external collaborations. In essence, the CEEDD (Center of Excellence for External Drug Discovery) will 'virtualize' a portion of the GSK pipeline; namely, from Target to Clinical PoC, by forming multiple risk-sharing/reward-sharing alliances.
About EPIX
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma. For more information, please visit the company's website at www.epixpharma.com.
This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10- K and subsequent Quarterly Reports on Form 10-Q.
EPIX
Kim C. Drapkin, 781-761-7602
Chief Financial Officer
or
Pure Communications
Jennifer Beugelmans, 646-596-7473
